Journal of Neurorestoratology (Mar 2021)

Standards of induced pluripotent stem cells derived clinical-grade neural stem cells preparation and quality control (2021 China version)

  • Meng Cai,
  • Fabin Han,
  • Nanxiang Xiong,
  • Yihao Wang,
  • Shiqing Feng,
  • Jiajing Wang,
  • Xiang Li,
  • Jun Wei,
  • Changkai Sun

DOI
https://doi.org/10.26599/JNR.2021.9040005
Journal volume & issue
Vol. 9, no. 1
pp. 13 – 30

Abstract

Read online

Induced pluripotent stem cells (iPSCs) have become the leading research object in the clinical application of restorative medicine. They are easily generated from diverse cell sources and functionally indistinguishable from embryonic stem cells without the accompanying ethical issues. To date, the use of iPSC-derived neural stem cells and their progeny in the treatment of neurodegenerative and injurious diseases has achieved good results, with great potential in cell drug development. However, because of some unique biological properties and differences from traditional drug production processes, cell drug research and development has many problems that can hinder clinical applications. Given this situation, the Chinese Association of Neurorestoratology (Preparatory) and China Committee of the International Association of Neurorestoratology have organized relevant professional experts to formulate the standard presented here. Overall, the aim was to promote the clinical application of neural stem cells (NSCs) and their further derived neural cells from iPSC sources and promote cell drugs’ production and development. This standard refers to the latest research results, quality evaluation criteria for traditional medicines, and the regulatory framework for cellular treatments. The standard considers general biological properties of cells, including cell morphology, cell cycle, karyotype, and cell viability. The specific biological properties of NSCs, such as cell surface markers and differentiation ability, general drug standards, such as aseptic testing, endotoxins, human virus detection, and cell-related drug standards, such as telomerase activity and tumorigenicity, are also considered. This standard will serve as a reference for physicians and scientists who focus on clinical nervous cell applications and studies related to iPSCs.

Keywords